Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice

Hepatology

Volumn 61, Issue 1, 2015, Pages 129-140

  Lazaro, Raul ^a,b   Wu, Raymond ^a,b   Lee, Sunyoung ^a,b   Zhu, Nian Ling ^a,b   Chen, Chia Lin ^a,b   French, Samuel W ^a,c   Xu, Jun ^a,b   Machida, Keigo ^a,b   Tsukamoto, Hidekazu ^a,b,d  

^a Southern California Research Center for ALPD and Cirrhosis   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; CXCL1 CHEMOKINE; CYTOKINE; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 17; OSTEOPONTIN; SATURATED FATTY ACID; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NANOG; ALPHA FETOPROTEIN; SPP1 PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ALCOHOL LIVER DISEASE; ALCOHOLIC NEUTROPHILIC HEPATITIS; ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; DISEASE ASSOCIATION; ENTERIC FEEDING; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; LIPID DIET; LIVER PARENCHYMA; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; SPLENOMEGALY; UPREGULATION; WESTERN DIET; WILD TYPE; ALCOHOLIC FATTY LIVER; ANIMAL; BINGE DRINKING; C57BL MOUSE; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ALPHA-FETOPROTEINS; ANIMALS; BINGE DRINKING; DISEASE MODELS, ANIMAL; FATTY LIVER, ALCOHOLIC; HEPATITIS, ALCOHOLIC; MALE; MICE, INBRED C57BL; NEUTROPHILS; OSTEOPONTIN; TOLL-LIKE RECEPTOR 4;

EID: 84920942866     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27383     Document Type: Article

References (42)

1. Choi G, Runyon BA. Alcoholic hepatitis: a clinician's guide. Clin Liver Dis 2012;16:371-385.
2. Maddrey WC, Boitnott JK, Bedine MS, Weber FL, Jr., Mezey E, White RI, Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
3. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010;51:307-328.
4. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol 2011;45:714-719.
5. Mathurin P, Lucey MR. Management of alcoholic hepatitis. J Hepatol 2012;56(Suppl 1):S39-S45.
6. Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014;12:555-564.
7. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011;141:1572-1585.
8. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638.
9. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111.
10. Xu J, Lai KK, Verlinsky A, Lugea A, French SW, Cooper MP, et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol 2011;55:673-682.
11. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007;41:761-772.
12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
13. Singal AK, Sagi S, Kuo YF, Weinman S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. Eur J Gastroenterol Hepatol 2011;23:204-209.
14. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. Acute alcoholic hepatitis. J Clin Gastroenterol 2006;40:833-841.
15. Zakhari S, Li TK. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology 2007;46:2032-2039.
16. Ueno A, Lazaro R, Wang PY, Higashiyama R, Machida K, Tsukamoto H. Mouse intragastric infusion (iG) model. Nat Protoc 2012;7:771-781.
17. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A 2009;106:1548-1553.
18. Ki SH, Park O, Zheng M, Morales-Ibanez O, Kolls JK, Bataller R, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology 2010;52:1291-1300.
19. Bertola A, Park O, Gao B. Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: a critical role for E-selectin. Hepatology 2013;58:1814-1823.
20. Apte UM, Banerjee A, McRee R, Wellberg E, Ramaiah SK. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol Appl Pharmacol 2005;207:25-38.
21. Morales-Ibanez O, Dominguez M, Ki SH, Marcos M, Chaves JF, Nguyen-Khac E, et al. Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. Hepatology 2013;58:1742-1756.
22. Banerjee A, Apte UM, Smith R, Ramaiah SK. Higher neutrophil infiltration mediated by osteopontin is a likely contributing factor to the increased susceptibility of females to alcoholic liver disease. J Pathol 2006;208:473-485.
23. Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, et al. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012;7:e35612.
24. Koh A, da Silva AP, Bansal AK, Bansal M, Sun C, Lee H, et al. Role of osteopontin in neutrophil function. Immunology 2007;122:466-475.
25. Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-115.
26. Ge X, Leung TM, Arriazu E, Lu Y, Urtasun R, Christensen B, et al. Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-alpha and prevents early alcohol-induced liver injury in mice. Hepatology 2014;59:1600-1616.
27. Ge X, Lu Y, Leung TM, Sorensen ES, Nieto N. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. Am J Physiol Gastrointest Liver Physiol 2013;304:G929-G939.
28. Maltby J, Wright S, Bird G, Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology 1996;24:1156-1160.
29. Dominguez M, Miquel R, Colmenero J, Moreno M, Garcia-Pagan JC, Bosch J, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009;136:1639-1650.
30. Lafdil F, Miller AM, Ki SH, Gao B. Th17 cells and their associated cytokines in liver diseases. Cell Mol Immunol 2010;7:250-254.
31. Lemmers A, Moreno C, Gustot T, Marechal R, Degre D, Demetter P, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646-657.
32. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012;143:765-776.
33. Scheiermann P, Bachmann M, Goren I, Zwissler B, Pfeilschifter J, Muhl H. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am J Pathol 2013;182:1107-1113.
34. Zindl CL, Lai JF, Lee YK, Maynard CL, Harbour SN, Ouyang W, et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci U S A 2013;110:12768-12773.
35. Feng D, Kong X, Weng H, Park O, Wang H, Dooley S, et al. Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 2012;143:188-198.
36. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012;56:1150-1159.
37. Sancho-Bru P, Altamirano J, Rodrigo-Torres D, Coll M, Millan C, Jose LJ, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology 2012;55:1931-1941.
38. Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, et al. Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells. J Clin Invest 2013;123:2832-2849.
39. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 2012;109:9448-9453.
40. Yuan QX, Marceau N, French BA, Fu P, French SW. Mallory body induction in drug-primed mouse liver. Hepatology 1996;24:603-612.
41. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013;155:384-396.
42. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, et al. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 2011;10:150.